Mangoceuticals (MGRX)
Connects telehealth customers with prescribers and pharmacies for prescription wellness products.
Something off on this page? Send us feedback.
Connects online customers to independent prescribers and pharmacies for MangoRx and PeachesRx prescription wellness products, earning mainly from product sales. Its telehealth model relies on contracted clinicians and a principal related-party pharmacy controlled by its founder and chief executive.
Connects customers through branded websites with independent licensed prescribers and third-party pharmacies that compound or dispense and ship prescription wellness products. The MangoRx portfolio spans erectile-dysfunction treatment, hair loss, hormone support, weight management and an oral testosterone product, while PeachesRx serves women's telehealth and the Direct programs provide consultation, care and support for branded weight-management medicines.
Generates revenue primarily from online prescription-product sales and recognizes it upon handoff to the carrier. Recurring subscriptions, privacy and rapid-dissolve or sublingual delivery shape the customer offer across a footprint covering most U.S. states; Mexico and UK operations remain limited.
Relies on contracted clinicians for medical decisions and Epiq Scripts for principal fulfillment. Epiq Scripts is controlled by founder and chief executive Jacob D. Cohen, and several compounded formulas are not FDA-approved or supported by clinical studies of their exact combinations and doses.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $228.7K · Total debt $324.2K · Total assets $14.2M · Shareholders' equity $12.5M
- Revenue
- $68.8K
- Operating income
- −$1.0M
- Net income
- −$1.3M
No dividends on record.
| Institutions18 holders · as of Mar 31, 2026 | 3.83% | 826.5K shares | |
| Insiders5 holders · as of Mar 20, 2026 | 4.16% | 896.7K shares | |
| Otherremainder | 92.01% | 19.84M shares |
21.57M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (21.57M in the company's Sep 3, 2026 report, 16.97M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Jacob D. CohenInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 2.32% | 500,000 | Form 4filed Mar 20, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.90% | 194,482 | 13Fas of Mar 31, 2026 |
Ikarian Capital, LLCInstitution | 0.64% | 138,146 | 13Fas of Mar 31, 2026 |
Lorraine Pamela D'AlessioInsiderdirector | 0.63% | 136,667 | Form 4filed Sep 12, 2025 ↗ |
Kenny MyersInsiderdirector | 0.63% | 136,667 | Form 4filed Sep 12, 2025 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 15, 2025 | Eugene M. Johnston | officer: CFO | −3,333 | $1.17 |
| Dec 9, 2025 | Eugene M. Johnston | officer: CFO | −5,000 | $1.20 |
| Dec 5, 2025 | Eugene M. Johnston | officer: CFO | −10,000 | $1.13 |
| Nov 19, 2025 | Alex P. Hamilton | director | −125,000 | $1.22 |
- Hims & Hers Health
Broad DTC overlap in sexual health, hair, hormones and weight care.
- LifeMD
Direct telehealth overlap in ED, hair loss and GLP-1 weight management.
- Eli Lilly
Zepbound and LillyDirect contest branded GLP-1 access and obesity-care spend.
- Novo Nordisk (ADR)
Wegovy and Ozempic compete for GLP-1 patients and Direct-program prescriptions.
- Merck
Propecia offers a branded finasteride alternative for hair-loss patients.
- Kenvue
Rogaine's branded minoxidil competes for hair-regrowth customers.
- Pfizer
Viagra is an approved ED alternative to a compounded rapid-dissolve tablet.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mangoceuticals | $0.3800 | −2.56% | $6.5M | — | — | 20.7 | −59.1% |
| Hims & Hers Health | $28.76 | +0.35% | $6.40B | — | 109.9 | 2.5 | +38.3% |
| LifeMD | $3.07 | −1.13% | $148.5M | — | — | 0.7 | −24.0% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Novo Nordisk (ADR) | $47.46 | +1.51% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Merck | $151.72 | +0.05% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Kenvue | $19.07 | −0.28% | $36.73B | 22.0 | 16.0 | 2.4 | +3.0% |
| Pfizer | $28.98 | −0.17% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Median | 38.3 | 18.2 | 2.6 | +3.0% |